香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立之股份有限公司） （股份代號 ： 1065） 建議終止部分募投項目的公告 茲提述天津創業環保集團股份有限公司（「本公司」）日期同為2021年11月22日有 關(1)終止2020年度經調整的非公開發行A股股票事項；(2)建議非公開發行A股； (3)特別授權；及(4)建議採納股東回報規劃的相關公告及海外監管公告，日期為 2021年12月8日的相關通函（「該通函」），日期為2021年12月8日的2021年第四次臨 時股東大會通告及2021年第二次H股類別股東大會通告，日期為2021年12月10日 有關非公開發行A股股票獲得天津市國資委批覆的公告，日期為2021年12月24日 的2021年第四次臨時股東大會、2021年第二次H股類別股東大會及2021年第二次 A股類別股東大會決議公告，日期為2022年1月11日有關非公開發行A股股票申 請獲得中國證監會受理的公告，日期為2022年2月7 ...

Core Viewpoint - The company, Diou Home Group Co., Ltd., is expected to report a significant loss in the first half of 2025, leading to a downgrade in its credit rating by Dongfang Jincheng International Credit Rating Co., Ltd. [1][2] Financial Performance - Diou Home Group anticipates a net loss attributable to shareholders of between 75 million yuan and 95 million yuan for the first half of 2025, which represents an increase in losses compared to the same period last year [1][2]. - The increase in credit impairment losses is attributed to the aging structure of receivables and specific provisions made during the period [2]. - The deferred income tax expense has increased compared to the previous year due to the reversal of impairment provisions related to non-cash asset settlements and asset disposals [2]. Fund Utilization - The company has decided to change the use of funds raised from the issuance of "Diou Convertible Bonds," reallocating 47.65843 million yuan of surplus funds to permanently supplement working capital [3]. - This decision was approved by the company's fourth extraordinary general meeting of 2025 and the first bondholders' meeting for "Diou Convertible Bonds" in 2025 [3].

Summary of Key Points Core Viewpoint The company, Shandong Linuo Pharmaceutical Packaging Co., Ltd., has decided to change the use of part of the raised funds from its convertible bond issuance to better align with its current development needs and strategic planning. Group 1: Fundraising Overview - The company issued 5 million convertible bonds with a total fundraising amount of 500 million RMB, netting 491.44 million RMB after deducting fees [1][2] - The original project for the raised funds was the industrialization of lightweight pharmaceutical molded glass bottles, with a total investment of 641.87 million RMB [2][4] - As of August 10, 2025, 126.05 million RMB of the raised funds had been utilized, leaving an unused amount [2][4] Group 2: Change in Fund Usage - The company plans to reallocate 154 million RMB from the original project to two new projects: acquiring a 30% stake in Chuangyang Co. and the second phase of the high-end pharmaceutical packaging project [2][5] - The new projects include an investment of 84 million RMB for the acquisition and 70 million RMB for the high-end packaging project [2][5] Group 3: Rationale for Change - The original project faced delays due to late delivery of construction facilities and lengthy customer certification processes, leading to a reduced funding requirement [4][5] - The company received a government subsidy of 89.58 million RMB for the original project, further decreasing the need for raised funds [4][5] Group 4: New Investment Projects - The acquisition of a 30% stake in Chuangyang Co. aims to enhance the company's product offerings and market share in pharmaceutical packaging [5][8] - The second phase of the high-end packaging project focuses on RTU (Ready-to-Use) packaging and pre-filled syringes, with a total investment of 383.37 million RMB [9][10] - The project is expected to have a payback period of 6.82 years and an internal rate of return of 16.37% [9] Group 5: Strategic Importance - The new projects align with the growing demand for high-quality pharmaceutical packaging driven by trends in the pharmaceutical industry [10][11] - The company aims to transition from a traditional pharmaceutical glass manufacturer to a diversified high-end packaging solution provider [10][12] - The strategic shift is supported by national policies promoting the development of the pharmaceutical packaging industry [13][14] Group 6: Approval Process - The board of directors and the supervisory board have approved the change in fund usage, ensuring compliance with relevant regulations [16][17] - The independent directors also confirmed that the decision aligns with the company's interests and does not harm shareholder value [17][18]

Core Viewpoint - The company, Shandong Linuo Pharmaceutical Packaging Co., Ltd., is changing the use of part of the raised funds from its convertible bond issuance to better align with its strategic development needs and improve fund utilization efficiency [2][19]. Summary by Sections Fundraising Overview - The company issued 5 million convertible bonds with a net fundraising amount of RMB 491.4447 million, after deducting underwriting fees [2][3]. - As of August 10, 2025, a total of RMB 126.0511 million has been invested from the raised funds, with the remaining amount stored in dedicated bank accounts [3][5]. Change in Fund Usage - The company plans to change the use of RMB 154 million from the "Lightweight Pharmaceutical Glass Bottle (Class I) Industrialization Project" to invest in two new projects: acquiring 30% equity in Suzhou Chuangyang New Materials Technology Co., Ltd. and the second phase of the high-end pharmaceutical packaging project [3][4]. - The new projects include an investment of RMB 84 million for the equity acquisition and RMB 154 million for the high-end packaging project [3][6]. Reasons for Change - The original project faced delays due to late delivery of construction facilities and longer customer certification cycles, leading to a reduced need for the originally planned funds [5][6]. - The company received a government subsidy of RMB 89.58 million, which decreased the funding requirement for the original project [5][6]. New Investment Projects - The acquisition of 30% equity in Suzhou Chuangyang New Materials is aimed at enhancing the company's product offerings and market share in pharmaceutical packaging [6][10]. - The second phase of the high-end pharmaceutical packaging project focuses on the production of Ready-to-Use (RTU) packaging and pre-filled syringes, with a total investment of RMB 383.3725 million, of which RMB 70 million will come from the raised funds [10][11]. Impact of Changes - The changes in fund usage are expected to enhance the company's operational efficiency and long-term benefits without adversely affecting its existing business or financial status [19][20]. - The company will implement strict internal and external supervision of the fund usage to ensure compliance with relevant regulations [20][21].

Core Viewpoint - The report highlights significant growth in revenue and net profit for Kunming Chuanjin Nuo Chemical Co., Ltd. in the first half of 2025, indicating a strong financial performance and strategic investments in new projects [1][4]. Financial Performance - Operating revenue for the reporting period reached approximately CNY 1.74 billion, representing a 27.91% increase compared to the same period last year [1]. - Net profit attributable to shareholders was approximately CNY 177.50 million, marking a substantial increase of 166.51% year-on-year [1]. - The net cash flow from operating activities was approximately CNY 170.95 million, a remarkable increase of 423.23% compared to the previous year [1]. - Basic earnings per share were CNY 0.6457, up 166.49% from CNY 0.2423 in the same period last year [1]. Asset and Equity Position - Total assets at the end of the reporting period were approximately CNY 3.67 billion, reflecting a 1.66% increase from the previous year [3]. - Net assets attributable to shareholders increased to approximately CNY 2.64 billion, a rise of 3.91% year-on-year [3]. Strategic Investments - The company signed a project investment agreement with the Dongchuan District Government to construct a waste disposal project with a total investment of approximately CNY 350 million [4]. - The company approved an investment project in Egypt, which includes the production of various phosphate chemicals with an annual capacity of 800,000 tons of sulfuric acid and other related products [5][6].

Summary of Key Points Core Viewpoint The company, Jiahe Intelligent Technology Co., Ltd., is changing the use of raised funds from its convertible bond issuance to acquire all partnership interests in beyerdynamic GmbH & Co. KG, a well-known high-end audio equipment manufacturer, due to the current macroeconomic environment and market uncertainties affecting its original investment projects. Group 1: Fundraising and Investment Projects - The company raised a total of RMB 1,004 million through the issuance of 10,040,000 convertible bonds, with a net amount of RMB 993.91 million after deducting issuance costs [1][4][6] - The original investment projects included the production of 5 million bone conduction headphones, 9 million smartwatches, and 4.5 million smart glasses, which were initially planned to be operational by January 10, 2026 [4][9] - Due to changes in the macroeconomic environment and uncertainties in international trade, the company has postponed the operational date of these projects to January 10, 2028 [4][9] Group 2: Change in Fund Usage - The company plans to use RMB 70.4 million of the uninvested raised funds and its interest income to acquire all partnership interests in beyerdynamic GmbH & Co. KG [6][8] - The acquisition is expected to enhance the company's market competitiveness in the high-end audio sector and align with its strategic goals of high-end manufacturing and brand operation [12][14] Group 3: Financial Impact and Projections - The acquisition is projected to generate RMB 892 million in revenue for the company in 2026, with a gross margin exceeding 50% and a net margin over 10% [12][31] - The transaction is anticipated to significantly improve the company's financial metrics compared to the original investment projects, which had lower expected profitability [12][31] Group 4: Strategic Rationale - The acquisition of beyerdynamic is seen as a strategic move to accelerate the company's transition towards high-end, branded products, enhancing its global market presence [13][30] - The integration of beyerdynamic's established brand and technology is expected to complement the company's existing product lines and manufacturing capabilities, fostering innovation and market expansion [15][32][33]

Core Viewpoint - Jiahe Intelligent plans to change the use of part of its raised funds to acquire all limited partnership interests of beyerdynamic GmbH & Co. KG, enhancing its competitiveness in the high-end audio sector [1] Group 1: Fund Usage Change - Jiahe Intelligent intends to use 704 million yuan of unutilized raised funds and its interest income and investment returns for the acquisition of BD KG [1] - The funds were originally allocated for projects including the production of 5 million bone conduction headphones, 9 million smartwatches, and 4.5 million smart glasses [1] Group 2: Strategic Rationale - BD KG is a globally recognized high-end audio equipment brand and manufacturer, aligning with Jiahe Intelligent's business in the electroacoustic industry [1] - The acquisition is expected to significantly enhance Jiahe Intelligent's market competitiveness in the high-end audio field and improve overall profitability [1] Group 3: Financial Efficiency - The change in fund usage is projected to improve the efficiency of raised fund utilization and increase the overall capital utilization rate for the company [1] - This strategic move is deemed beneficial for the company and all shareholders [1]

此外，鸿达兴业通过虚增营业收入以及虚减营业成本、费用等方式虚增利润总额，导致2020年至 2022年年度报告、2023年半年度报告涉嫌存在虚假记载。上述期间虚增利润总额分别占公司当期披露利 润总额（绝对值）高达94.11%、94.42%、618.70%和12.84%。涉案期间虚增营业收入合计35.05亿元， 虚增利润总额合计40.78亿元。 已从深市退市一年的鸿达兴业股份有限公司（简称"鸿达兴业"，NQ400207）拟被重罚。江苏证监 局日前发出的《行政处罚事先告知书》显示，因涉嫌擅自改变可转债募集资金用途、多年财务造假、重 大诉讼、仲裁未依法披露等事项，江苏证监局拟对鸿达兴业、实控人及7名董监高人员开出合计5800万 元罚单。其中，公司拟被罚1850万元；实控人、董事长兼总经理周奕丰拟被罚2200万元，终身证券市场 禁入；财务总监林桂生拟被罚600万元，10年证券市场禁入。 对于擅自改变可转债募集资金用途、财务造假等严重违法行为，监管部门对鸿达兴业及周奕丰均拟 实施顶格处罚。监管部门认为，周奕丰组织、指使公司在相关定期报告中编造、篡改重要财务数据，严 重扰乱证券市场秩序，组织、指使公司擅自变更募集资金用途； ...

Core Viewpoint - The company is adjusting the use of part of the raised funds to better align with market demands and internal development needs, specifically by reallocating funds from a gummy production line to a liquid production line, which reflects the industry's trend towards diversification and new product forms [5][8]. Summary by Sections Fundraising Overview - The company raised a total of RMB 3,125.35 million by issuing 119,288,209 shares at a price of RMB 26.20 per share in April 2021, with a net amount after expenses being confirmed by an auditing firm [1][2]. Project Change Details - The "Zhuhai Production Base Phase IV Expansion and Upgrade Project" originally planned to optimize existing facilities for dietary supplements, with a total investment of RMB 437.52 million, fully funded by the raised capital. As of June 30, 2025, RMB 82.31 million has been utilized, generating economic benefits of RMB 90.93 million [2][5]. Reasons for Change - The shift in product lifecycle and market demand has led to a strategic decision to pause the gummy production line and introduce a liquid production line, reallocating RMB 11.92 million from the gummy line to the new liquid line. This change represents 0.39% of the actual net raised funds [5][6]. Economic Benefit Analysis - The project is expected to generate annual revenue of RMB 1,248.41 million and a post-tax profit of RMB 148.65 million upon reaching full production capacity [5][6]. Approval Process - The project has received necessary approvals from relevant authorities, including the Zhuhai Development and Reform Bureau, and will continue to follow regulatory procedures as required [6][7]. Impact of Fund Use Change - The adjustment in fund usage is deemed reasonable and beneficial for improving fund efficiency and resource allocation, aligning with the company's operational needs without adversely affecting normal business operations [7][8]. Review Opinions - The board of directors, audit committee, and supervisory committee have all approved the changes, affirming that the adjustments are necessary for the company's strategic development and do not harm shareholder interests [7][8]. Sponsor's Verification - The sponsor, CITIC Securities, has confirmed that the changes comply with relevant regulations and have undergone the necessary review processes, pending shareholder approval for implementation [8][9].

Group 1 - The company held its fifth board meeting of 2025, where all members ensured the accuracy and completeness of the disclosed information [1] - The board approved a proposal to change the use of part of the raised funds from the 2022 stock issuance, reallocating 365.8654 million yuan to a new project focused on green low-carbon technology for data centers [1][2] - The total investment for the new project is 413.9781 million yuan, with the company planning to use 365.8654 million yuan from the raised funds [2] Group 2 - The board agreed to amend certain provisions of the company's articles of association to comply with legal regulations and improve business operations [3][4] - The board also approved revisions to the rules governing shareholder meetings to enhance order and efficiency [3] - The board's decisions, including the amendments to governance structures, will be submitted for approval at the upcoming second extraordinary general meeting of shareholders in 2025 [5]